Last reviewed · How we verify
3 months DAPT
Shanghai MicroPort Medical's 3 months DAPT is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its current market presence and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | 3 months DAPT |
|---|---|
| Also known as | Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day), Aspirin + clopidogrel for 3-months schedule after the coronary stenting |
| Sponsor | Shanghai MicroPort Medical (Group) Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SIMPLAAFY Clinical Trial (NA)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome (PHASE3)
- Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial) (PHASE3)
- Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2 (NA)
- Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation (NA)
- Ticagrelor De-escalation Strategy in AMI Patients (PHASE4)
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3 months DAPT CI brief — competitive landscape report
- 3 months DAPT updates RSS · CI watch RSS
- Shanghai MicroPort Medical (Group) Co., Ltd. portfolio CI